Skip to main content
. 2023 Dec 15;62(1):33–41. doi: 10.1080/13880209.2023.2292266

Figure 4.

Figure 4.

SFI facilitates the gefitinib cytotoxicity of PC9/GR and H1975 cells. (A, B) Cell proliferation inhibition profiles were measured after 48 h of different concentrations of gefitinib (30, 15, 7.5, 3.25 μmol/L), respectively co-administered IL-22 (50 ng/mL) alone or in combination with SFI (10 mg/mL) exposure to PC9/GR and H1975 cells. (C) Clonogenic assays of PC9/GR and H1975 cells after gefitinib alone, gefitinib + IL-22, gefitinib + SFI, and gefitinib + IL-22 + SFI treatment for 13 days. (D) After 48 h incubation with different schemes, including gefitinib alone, gefitinib + IL-22, gefitinib + SFI, and gefitinib + IL-22 + SFI, flow cytometric analysis of apoptosis was detected, and the data were processed by FlowJo VX software. Results are expressed as mean ± SEM (n = 3) *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001, when compared with gefitinib; ##p < 0.01, ###p < 0.001, ####p < 0.001 when compared with gefitinib + IL-22.